HCPLive
@hcplivenews.bsky.social
Everything you need to enhance your approach to improving patient care.
New from #ASH2025: We sat down with Crawford Strunk, MD, associate staff member at the Cleveland Clinic, to discuss the value of incorporating palliative care into comprehensive sickle cell disease care.
Watch now:
Watch now:
Palliative Care Improves Outcomes in Patients with SCD, With Crawford Strunk, MD | HCPLive
Strunk highlights reduced length of stay and superior outpatient pain management due to palliative care in hospitalized patients.
www.hcplive.com
December 9, 2025 at 3:00 PM
New from #ASH2025: We sat down with Crawford Strunk, MD, associate staff member at the Cleveland Clinic, to discuss the value of incorporating palliative care into comprehensive sickle cell disease care.
Watch now:
Watch now:
Finerenone reduces proteinuria by ~40% in IgA nephropathy over 8 months with stable eGFR, according to new research.
Early real-world evidence supports further study in glomerular disease.
Learn more:
Early real-world evidence supports further study in glomerular disease.
Learn more:
Finerenone Shows Promise in IgAN: Reduced Proteinuria, Stable Kidney Function | HCPLive
A retrospective cohort in finerenone showed nearly 40% proteinuria reduction at 8 months and stable eGFR in patients with IgA nephropathy.
www.hcplive.com
December 9, 2025 at 1:01 PM
Finerenone reduces proteinuria by ~40% in IgA nephropathy over 8 months with stable eGFR, according to new research.
Early real-world evidence supports further study in glomerular disease.
Learn more:
Early real-world evidence supports further study in glomerular disease.
Learn more:
New findings suggest topical #roflumilast 0.3% significantly improves #psoriasis outcomes, including IGA and PASI scores, compared to placebo.
The systematic review and meta-analysis involved five RCTs with 1835 participants.
View more:
The systematic review and meta-analysis involved five RCTs with 1835 participants.
View more:
Topical Roflumilast 0.3% Effective, Safe in Systematic Review of Psoriasis Data | HCPLive
This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.
www.hcplive.com
December 9, 2025 at 4:00 AM
New findings suggest topical #roflumilast 0.3% significantly improves #psoriasis outcomes, including IGA and PASI scores, compared to placebo.
The systematic review and meta-analysis involved five RCTs with 1835 participants.
View more:
The systematic review and meta-analysis involved five RCTs with 1835 participants.
View more:
New phase 3 data show adjunctive lumateperone 42 mg significantly improves #MDD symptoms by day 43, reinforcing its 2025 FDA approval. Read more: www.hcplive.com/view...
December 9, 2025 at 2:00 AM
New phase 3 data show adjunctive lumateperone 42 mg significantly improves #MDD symptoms by day 43, reinforcing its 2025 FDA approval. Read more: www.hcplive.com/view...
Had a hectic November? Catch up on the biggest news in endocrinology with our HCPLive Month in Review, and follow @hcplive for the most impactful news in medicine!
www.hcplive.com/view...
www.hcplive.com/view...
December 7, 2025 at 5:00 PM
Had a hectic November? Catch up on the biggest news in endocrinology with our HCPLive Month in Review, and follow @hcplive for the most impactful news in medicine!
www.hcplive.com/view...
www.hcplive.com/view...
Catch up on any cardiology news you may have missed last month with our HCPLive Cardiology Month in Review!
Read now: www.hcplive.com/view...
Read now: www.hcplive.com/view...
December 6, 2025 at 10:00 PM
Catch up on any cardiology news you may have missed last month with our HCPLive Cardiology Month in Review!
Read now: www.hcplive.com/view...
Read now: www.hcplive.com/view...
Patients with impaired kidney function are linked to elevated Alzheimer's Disease blood biomarkers, but are not at an increased risk for dementia, according to new data from a study in older adults. Read more:
Impaired Kidney Function Linked to Alzheimer’s Biomarkers But Not Dementia | HCPLive
Findings suggest people with reduced kidney function have higher levels of Alzheimer’s biomarkers in their blood but not an increased risk of dementia.
www.hcplive.com
December 6, 2025 at 5:00 PM
Patients with impaired kidney function are linked to elevated Alzheimer's Disease blood biomarkers, but are not at an increased risk for dementia, according to new data from a study in older adults. Read more:
New AI-assisted genetic tool shows promise in guiding MDD treatment with vasopressin blockers. Blood test identifies patients likely to respond, #MDD #PrecisionMedicine www.hcplive.com/view/new-gen...
New Genetic Tool Shows Promise for Targeted MDD Treatment, With Hans Eriksson, PhD, MD | HCPLive
As the FDA strengthens AI standards after its recent meeting, a new AI-assisted genetic tool shows promise for pinpointing patients who may respond to a vasopressin blocker.
www.hcplive.com
December 5, 2025 at 10:05 PM
New AI-assisted genetic tool shows promise in guiding MDD treatment with vasopressin blockers. Blood test identifies patients likely to respond, #MDD #PrecisionMedicine www.hcplive.com/view/new-gen...
We spoke with Ozlem Bilen, MD, chief of cardiology at Emory University Hospital, to discuss the recent success of the COLLIGO-HCM trial and mavacamten's proven efficacy in improving cardiac function in patients with obstructive HCM.
Watch now:
Watch now:
Mavacamten Monotherapy Improves Cardiac Function in oHCM, With Ozlem Bilen, MD | HCPLive
Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.
www.hcplive.com
December 4, 2025 at 3:00 PM
We spoke with Ozlem Bilen, MD, chief of cardiology at Emory University Hospital, to discuss the recent success of the COLLIGO-HCM trial and mavacamten's proven efficacy in improving cardiac function in patients with obstructive HCM.
Watch now:
Watch now:
Pulmonology is shifting towards precision medicine, emphasizing biomarker research and biologic therapies for COPD, challenging traditional disease categorizations. Hear from experts from @TempleHealth and @MountSinaiNYC on the shift in our #ThisYearinMedicine feature now:
Rewriting Airway Disease With Trait-Based Care: 2025’s Convergence of Asthma and COPD Management | HCPLive
Discover how precision medicine reshapes COPD treatment, focusing on inflammation and patient-specific traits for improved outcomes in airway diseases.
www.hcplive.com
December 4, 2025 at 1:00 PM
Pulmonology is shifting towards precision medicine, emphasizing biomarker research and biologic therapies for COPD, challenging traditional disease categorizations. Hear from experts from @TempleHealth and @MountSinaiNYC on the shift in our #ThisYearinMedicine feature now:
Among older adults receiving maintenance hemodialysis, improving physical fitness and nutrition can protect from sarcopenia.
Learn more:
Learn more:
Risk Factors for Sarcopenia in Older Adults on MHD Include Physical Activity, Nutrition | HCPLive
A multicenter study outlines stage-specific risk factors, protective traits for sarcopenia in older adults on maintenance hemodialysis, supporting earlier screening.
www.hcplive.com
December 4, 2025 at 4:00 AM
Among older adults receiving maintenance hemodialysis, improving physical fitness and nutrition can protect from sarcopenia.
Learn more:
Learn more:
INF904 shows rapid, meaningful improvements in HS & CSU with no safety signals in Phase 2a, supporting plans for Phase 2b trials. #Dermatology #HS #CSU
INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals | HCPLive
The oral C5aR inhibitor produced durable responses across multiple doses in an 8-week trial, prompting InflaRx to move forward with phase 2b development.
www.hcplive.com
December 4, 2025 at 2:00 AM
INF904 shows rapid, meaningful improvements in HS & CSU with no safety signals in Phase 2a, supporting plans for Phase 2b trials. #Dermatology #HS #CSU
We spoke with C. Michael Gibson, MD, CEO of the Baim and PERFUSE research centers at Harvard Medical School, to discuss the promising new data from COLLIGO-HCM, which saw zalunfiban improve STEMI outcomes prior to arriving at the hospital.
Watch now:
Watch now:
CeleBrate: Zalunfiban Administration at First Contact Improves STEMI Outcomes, With C. Michael Gibson, MD | HCPLive
Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.
www.hcplive.com
December 3, 2025 at 3:00 PM
We spoke with C. Michael Gibson, MD, CEO of the Baim and PERFUSE research centers at Harvard Medical School, to discuss the promising new data from COLLIGO-HCM, which saw zalunfiban improve STEMI outcomes prior to arriving at the hospital.
Watch now:
Watch now:
Pulmonary rehabilitation significantly reduced FeNO levels in asthma patients with high baseline FeNO, indicating its potential as a complementary asthma management strategy. Read more:
Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma | HCPLive
PR was seen to reduce FeNO, a biomarker of type 2 inflammation, in a new study.
www.hcplive.com
December 3, 2025 at 1:00 PM
Pulmonary rehabilitation significantly reduced FeNO levels in asthma patients with high baseline FeNO, indicating its potential as a complementary asthma management strategy. Read more:
The 8 Nephrology Headlines You Missed in November 2025 include meaningful updates on immune-targeted IgAN therapies, FDA designations for rare kidney disorders, and transplant/immunosuppression data.
Read a recap of the top renal news and research from the past few weeks:
Read a recap of the top renal news and research from the past few weeks:
8 Nephrology Headlines You Missed in November 2025 | HCPLive
Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.
www.hcplive.com
December 3, 2025 at 4:00 AM
The 8 Nephrology Headlines You Missed in November 2025 include meaningful updates on immune-targeted IgAN therapies, FDA designations for rare kidney disorders, and transplant/immunosuppression data.
Read a recap of the top renal news and research from the past few weeks:
Read a recap of the top renal news and research from the past few weeks:
@BiofronteraInc announced the submission of a supplemental New Drug Application (sNDA) to the #FDA for Ameluz-PDT (photodynamic therapy) as a treatment for superficial basal cell carcinoma.🔍
🔗View more here:
www.hcplive.com/view...
#dermatology #SkinCancer
🔗View more here:
www.hcplive.com/view...
#dermatology #SkinCancer
sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA | HCPLive
Biofrontera announced its submission of a supplemental New Drug Application to the FDA for Ameluz-PDT in superficial basal cell carcinoma (sBCC).
www.hcplive.com
December 3, 2025 at 2:00 AM
@BiofronteraInc announced the submission of a supplemental New Drug Application (sNDA) to the #FDA for Ameluz-PDT (photodynamic therapy) as a treatment for superficial basal cell carcinoma.🔍
🔗View more here:
www.hcplive.com/view...
#dermatology #SkinCancer
🔗View more here:
www.hcplive.com/view...
#dermatology #SkinCancer
On the morning of December 1, the FDA announced acceptance of the supplemental NDA for the FUROSCIX ReadyFlow Autoinjector, which delivers furosemide treatment to patients with CHF and CKD in under 10 seconds.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
December 2, 2025 at 3:00 PM
On the morning of December 1, the FDA announced acceptance of the supplemental NDA for the FUROSCIX ReadyFlow Autoinjector, which delivers furosemide treatment to patients with CHF and CKD in under 10 seconds.
Read more: www.hcplive.com/view...
Read more: www.hcplive.com/view...
Phase 2 evidence presented at #ASN2025 of the factor D-targeted therapy, ALXN2050, highlights emerging safety concerns and lack of efficacy.
Sayna Norouzi, MD, discusses the trial’s early termination and what it means for the future of IgAN targeted therapies.
Learn more:
Sayna Norouzi, MD, discusses the trial’s early termination and what it means for the future of IgAN targeted therapies.
Learn more:
Factor D Inhibition Lacks Efficacy For IgAN in Phase 2 ALXN2050 Trial, With Sayna Norouzi, MD | HCPLive
The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.
www.hcplive.com
December 2, 2025 at 1:00 PM
Phase 2 evidence presented at #ASN2025 of the factor D-targeted therapy, ALXN2050, highlights emerging safety concerns and lack of efficacy.
Sayna Norouzi, MD, discusses the trial’s early termination and what it means for the future of IgAN targeted therapies.
Learn more:
Sayna Norouzi, MD, discusses the trial’s early termination and what it means for the future of IgAN targeted therapies.
Learn more:
Tezepelumab drastically reduced steroid use for #asthma, although the trial's open-label design means more research is still needed. Read more:
Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial | HCPLive
However, a related editorial from University of Rome was quick to point out possibly sizable placebo effects in the trial.
www.hcplive.com
December 2, 2025 at 4:00 AM
Tezepelumab drastically reduced steroid use for #asthma, although the trial's open-label design means more research is still needed. Read more:
New research is shedding light on state- and local-level geographic disparities in the availability of gastroenterologist care, highlighting limited access to care in rural areas and areas with low household incomes relative to urban areas.
Learn more: www.hcplive.com/view...
Learn more: www.hcplive.com/view...
December 2, 2025 at 2:00 AM
New research is shedding light on state- and local-level geographic disparities in the availability of gastroenterologist care, highlighting limited access to care in rural areas and areas with low household incomes relative to urban areas.
Learn more: www.hcplive.com/view...
Learn more: www.hcplive.com/view...
In an interview with HCPLive, Brandon Yan, MD, University of California, addresses the gradual increase in cardiovascular disease mortality after the COVID-19 pandemic, and what can be done to address it.
Watch now:
Watch now:
Addressing Post-Pandemic Cardiovascular Mortality Rate Increases, With Brandon Yan, MD | HCPLive
Yan discusses the reversion of 50-year trends in mortality and the steps needed to reduce these rates back to pre-pandemic levels.
hcplive.com
November 30, 2025 at 3:00 PM
In an interview with HCPLive, Brandon Yan, MD, University of California, addresses the gradual increase in cardiovascular disease mortality after the COVID-19 pandemic, and what can be done to address it.
Watch now:
Watch now:
Kassandra Holzem, MD, of @MedicalCollege, sat down in an interview with HCPLive at the #SDPAFall2025. Holzem was asked about her session ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic.’
View her responses here:
View her responses here:
Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD | HCPLive
Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.
www.hcplive.com
November 29, 2025 at 5:00 PM
Kassandra Holzem, MD, of @MedicalCollege, sat down in an interview with HCPLive at the #SDPAFall2025. Holzem was asked about her session ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic.’
View her responses here:
View her responses here:
Rezpegaldesleukin shows strong phase 2b results, improving both #AtopicDermatitis severity and asthma control, especially in patients with uncontrolled asthma. #ACAAI2025
Read more here:
Read more here:
Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma | HCPLive
Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.
www.hcplive.com
November 29, 2025 at 3:00 PM
Rezpegaldesleukin shows strong phase 2b results, improving both #AtopicDermatitis severity and asthma control, especially in patients with uncontrolled asthma. #ACAAI2025
Read more here:
Read more here:
In the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the failure of semaglutide to meaningfully impact Alzheimer's disease progression in Novo Nordisk's recent trial.
Watch now:
Watch now:
Diabetes Dialogue: Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D | HCPLive
Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.
www.hcplive.com
November 28, 2025 at 8:00 PM
In the latest episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the failure of semaglutide to meaningfully impact Alzheimer's disease progression in Novo Nordisk's recent trial.
Watch now:
Watch now:
ICYMI: Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib.
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
SCALE-UP: Findings on Real-World Use of Upadacitinib in Atopic Dermatitis | HCPLive
The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.
hcplive.com
November 28, 2025 at 4:00 PM
ICYMI: Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib.
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗